FTSE NAREIT Equity Diversified (FN10)

Paysign: A Real Turnaround Trade That Leaves Little Room For Growth
Inbox

SA Analysis Unsubscribe
Jun 24, 2026, 11:50?PM (6 hours ago)
to me

Paysign: A Real Turnaround Trade That Leaves Little Room For Growth

$BURU Nuburu said the Italian plan represents about $336.3 million in projected gross revenue from 2026 to 2029. The company projects $13.1 million in 2026 and $74.4 million in 2027. It also projects $105.7 million in 2028 and $143.1 million in 2029.

$BURU Nuburu said the Italian plan represents about $336.3 million in projected gross revenue from 2026 to 2029. The company projects $13.1 million in 2026 and $74.4 million in 2027. It also projects $105.7 million in 2028 and $143.1 million in 2029.

Why after 2.5 years it has not been rejected? Quite unprecedented, isn’t it? Explain ! Beautiful things take time. 

The Rat is working 24/7. Should get some news soon.

How long till no bid? 🤣

Nexera Technologies Ltd. operates as an e-commerce consumer products goods company. It operates as a holding company of three other e-commerce companies that operate online stores for the sale of various consumer products on the Amazon online marketplace, utilizing the Fulfillment by Amazon, or FBA

Current sentiment among investor communities suggests moderate to high odds of approval for this specific Early Feasibility pathway, citing several key factors:

Stronger Data Package: The submission includes extensive human clinical data from India and outcomes from over 100 IsoPet ve

Forward Water Technologies Corp. Announces Secured Bridge Debenture FinancingJune 25, 2026 7:00 AM
PR Newswire (Canada) class="legendSpanClass"TORONTO, class="legendSpanClass"June 25, 2026 /CNW/ - Forward Water Technologies Corp. ("FWTC"

Nuvation Bio Announces Proposed Convertible Senior Notes OfferingJune 25, 2026 7:00 AM
PR Newswire (US) class="legendSpanClass"NEW YORK, class="legendSpanClass"June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB)

Veeva Introduces New EHS Application for Proactive Risk Management and Intelligent AutomationJune 25, 2026 7:03 AM
PR Newswire (US) Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insig

NeoGenomics Appoints Carolyn Starrett to its Board of DirectorsJune 25, 2026 7:05 AM
Business Wire

Germany’s Merck to Acquire Bio-Techne in $11.3 Billion DealJune 25, 2026 6:57 AM
IH Market News Germany’s Me

Moderna Science Day Highlights Expanding Potential of mRNA PlatformJune 25, 2026 7:00 AM
ACCESS NewswireProvides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation o

Greenspan Is Gone, But the Fed Put EnduresJune 25, 2026 7:00 AM
IH Market News Former Federal Reserve Chairman Alan Greenspa

Irving Resources Discovers High-Grade Feeder at Omu SinterJune 25, 2026 7:00 AM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / June 25, 2026 / Irving Resources Inc. (CSE:IRV)(OTCQX:IRV

Greenspan Is Gone, But the Fed Put EnduresJune 25, 2026 7:00 AM
IH Market News Former Federal Reserve Chairman Alan Greenspa

Market cap update: $20k
Future market cap: $5k

If I didn't think there wouldn't be sales I wouldn't remain invested. That would be insane! Hell yeah it would've been great for once-in-a-lifetime to have hit on demand. My due diligence showed me a long time ago, I was a fool for thinking it would. I mean, if it were so easy, anyone with more fund

I stopped reading his posts all together, waste of time.

Makes me drool 

Hey you did it again. Most likely, this will post will not age well. Maybe it will he your lucky draw after so many tries. Do they even have new capex numbers yet?

That seems to fit my fundamental vision on the next couple of weeks where we will see Traxys , FS and Exim approval.

🤬

The only thing that makes me potentially believe the dilution issue will be resolved in 2026 is the press release stating they are in ongoing negotiations of the legacy debt. If they actually succeed at substantially reducing or repacking these into preferred instruments for example, a major risk ha

If it is so obvious, then you should have no trouble answering the obvious question: why, after more than 2.5 years, is there still no approval?